Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma

Machida,Shizuo; Sato,Tomomi; Fujiwara,Hiroyuki; Saga,Yasushi; Takei,Yuji; Taneichi,Akiyo; Nonaka,Hiroaki; Suzuki,Mitsuaki

doi:10.3892/ol.2012.853

November 2012 Volume 4 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2012 Volume 4 Issue 5

Full Size Image

Article

Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma

Authors:
- Shizuo Machida
- Tomomi Sato
- Hiroyuki Fujiwara
- Yasushi Saga
- Yuji Takei
- Akiyo Taneichi
- Hiroaki Nonaka
- Mitsuaki Suzuki
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi 329-0498, Japan
Pages: 1017-1022
|
Published online on: August 6, 2012

https://doi.org/10.3892/ol.2012.853
Expand metrics +

Abstract

This study retrospectively compared nedaplatin and irinotecan hydrochloride (NDP/CPT) combination therapy with cisplatin and irinotecan hydrochloride therapy (CDDP/CPT) for efficacy and adverse events in the treatment of clear cell adenocarcinoma of the ovary (CCC) and recurrent ovarian carcinoma. A total of 115 patients were included in the present study. NDP/CPT was administered intravenously every 4 weeks (NDP, 60 mg/m2 on day 1; CPT, 50 mg/m2 on days 1, 8 and 15). CDDP/CPT was also administered intravenously (CDDP, 60 mg/m2 on day 1; CPT, 60 mg/m2 on days 1, 8 and 15). Patients with primary CCC were treated with NDP/CPT in 29 cases and CDDP/CPT in 20 cases. Patients with recurrent ovarian carcinoma were treated with NDP/CPT and CDDP/CPT in 33 cases each. No significant difference was observed in the 5-year overall survival (OS)/progression-free survival (PFS) of patients with primary CCC, with the exception of those patients with stages Ia and Ic(b) who underwent NDP/CPT and CDDP/CPT treatments (OS: 58%, PFS: 40% and OS: 53% and PFS: 47%, respectively). No significant differences were found in the response rates to NDP/CPT and CDDP/CPT in patients with recurrent ovarian carcinoma (27 and 18%, respectively). Similarly, there were no significant differences in the 5-year OS and PFS of patients with recurrent ovarian carcinoma treated with NDP/CPT or CDDP/CPT (OS: 15%, PFS: 3% and OS: 18%, PFS: 6%, respectively). In terms of the hematological toxicity of grade 3 or above and non-hematological toxicity of grade 2 or above in patients treated with NDP/CPT and CDDP/CPT, respectively, neutropenia was 23 and 56%; anemia, 1, and 20%; thrombocytopenia, 0 and 5%; nausea, 20 and 52%; diarrhea, 14 and 25%; and fever, 2 and 11%. Accordingly, NDP/CPT indicated mild toxicity, and was therefore equally effective and less toxic than CDDP/CPT in the treatment of primary CCC and recurrent ovarian carcinoma.

View Figures

View References

1.	SF SerovRE ScullyLH SobinInternational Histologic Classification of Tumors, No 9 Histological Typing of Ovarian TumorsWorld Health OrganizationGeneva1973
2.	AP HeintzF OdicinoP MaisonneuveCarcinoma of the ovary. FIGO 6th Annual Report on Results of Treatment in Gynecological CancerInt J Gynaecol Obstet95S161S192200617161157
3.	T SugiyamaT KamuraJ KigawaClinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapyCancer8825842589200010.1002/1097-0142(20000601)88:11%3C2584::AID-CNCR22%3E3.0.CO;2-510861437
4.	A Du BoisJ HerrstedtAC Hardy-BessardPhase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancerJ Clin Oncol28416241692010
5.	H UtsunomiyaJ AkahiraS TannoPaclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trialInt J Gynecol Cancer165256200610.1111/j.1525-1438.2006.00289.x16445610
6.	T EnomotoC KuragakiM YamasakiIs clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin?Proc Am Soc Clin Oncol22abs. 17972003
7.	M TakanoY KikuchiN YaegashiAdjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryOncol Rep1613011306200617089053
8.	M TakanoT SugiyamaN YaegashiProgression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecancisplatin: retrospective analysisInt J Clin Oncol12256260200710.1007/s10147-007-0670-117701003
9.	S TakakuraM TakanoF TakahashiRandomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG studyInt J Gynecol Cancer20240247201010.1111/IGC.0b013e3181cafb4720169667
10.	DM GershensonIrinotecan in epithelial ovarian cancerOncology (Williston Park)162931200212109803
11.	T SugiyamaM YakushijiT NishidaK UshijimaN OkuraJ KigawaN TerakawaIrinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancerCancer Lett128211218199810.1016/S0304-3835(98)00065-29683285
12.	S MachidaM OhwadaH FujiwaraPhase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancerOncology65102107200310.1159/00007233312931014
13.	T KatoH NishimuraM YakushijiPhase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancerGan To Kagaku Ryoho1969570119921580643
14.	T OtaN TakeshimaK TakizawaSecond-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?Eur J Gynaecol Oncol32471475201122053655
15.	M KoshiyamaM KinezakiT UchidaM SumitomoChemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatinAnticancer Res2544994502200516334133
16.	M NishidaH TsunodaY IchikawaH YoshikawaComplete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinomaInt J Clin Oncol9403405200410.1007/s10147-004-0413-515549593
17.	Y SasakiT AmanoM MoritaPhase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusionCancer Res511472147719911997185
18.	LS RosenIrinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancersOncology (Williston Park)1210310919989726101
19.	K YamamotoK KokawaN UmesakiPhase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group studyOncol Rep2110051009200910.3892/or_00000316
20.	F OshitaM OheT HondaPhase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancerBr J Cancer10313251323201010.1038/sj.bjc.660587520940720
21.	T MikiT NomotoS NakagawaThe salvage chemotherapy for refractory testicular cancer with novel anticancer agentsHinyokika Kiyo45811814199910637749
22.	T IshibashiY YanoT OgumaA formula for predicting optimal dose of nedaplatin based on renal function in adult cancer patientsCancer Chemother Pharmacol50230236200210.1007/s00280-002-0488-512203105
23.	S SatoH FujiwaraT OishiEvaluation of a formula for individual dosage of nedaplatin based on renal functionCancer Chemother Pharmacol69599603201210.1007/s00280-011-1739-021918903
24.	H MinamiK SaiM SaekiIrinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1^6 and ^28Pharmacogenet Genomics17497504200710.1097/FPC.0b013e328014341f17558305
25.	G ToffoliE CecchinG CoronaThe role of UGT1A1^*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancerJ Clin Oncol2430613068200616809730

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles